Mass spectrometry is only one piece of the puzzle in clinical proteomics

Briefings in Functional Genomics and Proteomics

Volumn 7, Issue 1, 2008, Pages 74-83

  Mcguire, James N ^a   Overgaard, Julie ^a   Pociot, Flemming ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

Biomarkers; Mass spectrometry; Proteomics

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN;

ARTICLE; AUTOMATION; BLOOD ANALYSIS; CLINICAL PROTOCOL; DATA ANALYSIS; DATA COLLECTION METHOD; DIABETES MELLITUS; DISEASE MARKER; GENETIC ALGORITHM; GENETIC HETEROGENEITY; HUMAN; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIVARIATE ANALYSIS; OVARY CANCER; PROTEIN ANALYSIS; PROTEIN STRUCTURE; PROTEOMICS; SAMPLING; STANDARDIZATION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

BIOLOGICAL MARKERS; CLINICAL LABORATORY TECHNIQUES; HUMANS; MASS SPECTROMETRY; PROTEOMICS;

ANIMALIA;

EID: 44249092618     PISSN: 14739550     EISSN: 14774062     Source Type: Journal    
DOI: 10.1093/bfgp/eln005     Document Type: Article

References (53)

1. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-78.
2. Hakonarson H, Grant SFA, Bradfield JP, et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 2007;448:591-4.
3. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007;445:881-5.
4. Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007;39:857-64.
5. Freimer NB, Sabatti C. Human genetics: Variants in common diseases. Nature 2007;445:828-30.
6. Lage K, Karlberg EO, Storling ZM, et al. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat Biotechnol 2007;25:309-16.
7. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-83.
8. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359 572-7.
9. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: Comparing datasets from different experiments. Bioinformatics 2004;20:777-85.
10. Bast RC, Jr, Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005; 15(Suppl 3):274-81.
11. Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 2006;52: 1223-37.
12. Carr SA, Celis JE. Biomarkers and clinical proteomics. Mol Cell Proteomics 2006;5:1719.
13. Mischak H, Apweiler R, Banks RE, et al. Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl 2007;1:148-56.
14. Anderson NL, Polanski M, Pieper R, et al. The human plasma proteome: A nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004;3:311-26.
15. Fenselau C. A review of quantitative methods for proteomic studies. J Chromatogr B 2007;855:14-20.
16. Baggerly KA, Morris JS, Edmonson SR, et al. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005;97:307-9.
17. McLerran D, Grizzle WE, Feng Z, et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 2008;54: 53-60.
18. McLerran D, Grizzle WE, Feng Z, et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer; sources of sample bias. Clin Chem 2008;54: 44-52.
19. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271-84.
20. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: Spinning biologic trash into diagnostic gold. J Clin Invest 2006;116 26-30.
21. Fung ET, Yip TT, Lomas L, et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 2005;115:783-9.
22. Simonsen AH, Andreasen N, Waldemar G, et al. Novel diagnostic biomarkers of Alzheimer's disease in human CSF. Neurobiol Aging 2004;25:S366.
23. Simonsen AH, McGuire J, Hansson O, et al. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 2007;64:366-70.
24. Anderson NL, Anderson NG. The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics: MCP 2002;1 845-67.
25. Lilley KS, Friedman DB. All about DIGE: Quantification technology for differential- display 2D-gel proteomics. Expert Rev Proteomics 2004;1:401-9.
26. Morrison RS, Kinoshita Y, Johnson MD, et al. Proteomic analysis in the neurosciences. Mol Cell Proteomics 2002;1: 553-60.
27. Villanueva J, Lawlor K, Toledo-Crow R, et al. Automated serum peptide profiling. Nat Protoc 2006;1:880-91.
28. Fortis F, Guerrier L, Areces LB, et al. A new approach for the detection and identification of protein impurities using combinatorial solid phase ligand libraries. J Proteome Res 2006;5:2577-85.
29. Righetti PG, Boschetti E, Lomas L, et al. Protein Equalizer (TM) technology: The quest for a 'democratic proteome'. Proteomics 2006;6:3980-92.
30. Righetti PG, Boschetti E. Sherlock Holmes and the proteome - a detective story. FEBS J 2007;274:897-905.
31. Thulasiraman V, Lin S, Gheorghiu L, et al. Reduction of the concentration difference of proteins in biological liquids using a library of combinatorial ligands. Electrophoresis 2005; 26 3561-71.
32. Chait BT. Mass Spectrometry: Bottom-up or top-down? Science 2006;314:65-6.
33. Cañas B, Lopez-Ferrer D, Ramos-Fernandez A, et al. Mass spectrometry technologies for proteomics. Brief Funct Genomics Proteomics 2006;4:295-320.
34. Rai AJ, Gelfand CA, Haywood BC, et al. HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples. Proteomics 2005;5 3262-77.
35. Chen EI, Hewel J, Felding-Habermann B, et al. Large scale protein profiling by combination of protein fractionation and multidimensional protein identification technology (MudPIT). Mol Cell Proteomics 2006;5:53-6.
36. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.
37. Fenn JB, Mann M, Meng CK, et al. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989; 246:64-71.
38. Tanaka K, Waki H, Ido Y, et al. Protein and polymer analyses up to m/z 100 000 by laser ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 1988;2: 151-3.
39. Schiffer E, Mischak H, Novak J. High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. Proteomics 2006;6:5615-27.
40. Gillette MA, Mani DR, Carr SA. Place of pattern in proteomic biomarker discovery. J Proteome Res 2005;4: 1143-54.
41. Semmes OJ, Feng Z, Adam BL, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102-12.
42. Zhang Z, Bast RC, Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64: 5882-90.
43. Orvisky E, Drake SK, Martin BM, et al. Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma. Proteomics 2006;6:2895-902.
44. Jolly RA, Goldstein KM, Wei T, et al. Pooling samples within microarray studies: A comparative analysis of rat liver transcription response to prototypical toxicants. Physiol Genomics 2005;22 346-55.
45. Saeys Y, Inza I, Larranaga P. A review of feature selection techniques in bioinformatics. Bioinformatics 2007;23:2507-17.
46. Semmes OJ, Cazares LH, Ward MD, et al. Discrete serum protein signatures discriminate between human retrovirus-associated hematologic and neurologic disease. Leukemia 2005;19:1229-38.
47. Evans JMM, Barnett KN, Ogston SA, et al. Increasing prevalence of type 2 diabetes in a Scottish population: Effect of increasing incidence or decreasing mortality?. Diabetologia 2007;50:729-32.
48. Anderson NL, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-88.
49. Guerreiro N, Gomez-Mancilla B, Charmont S. Optimization and evaluation of surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry for protein profiling of cerebrospinal fluid. Proteome Sci 2006;4:7.
50. Goodacre R. Metabolomics of a superorganism. J Nutr 2007;137 259S-66.
51. Ressine A, Corin I, Jar̈rias K, et al. Porous silicon surfaces - a candidate substrate for reverse protein arrays in cancer biomarker detection. Electrophoresis 2007;28:4407-15.
52. Weissinger EM, Wittke S, Kaiser T, et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 2004;65: 2426-34.
53. Peng S, Xu Q, Ling XB, et al. Molecular classification of cancer types from microarray data using the combination of genetic algorithms and support vector machines. FEBS Lett 2003;555:358-62.